Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells

Alectinib is a new generation ALK inhibitor with activity against the gatekeeper L1196M mutation that showed remarkable activity in a phase I/II study with echinoderm microtubule associated protein-like 4 (EML4) - anaplastic lymphoma kinase (ALK) non-small cell lung cancer (NSCLC) patients. However,...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Tanimoto, Azusa, Yamada, Tadaaki, Nanjo, Shigeki, Takeuchi, Shinji, Ebi, Hiromichi, Kita, Kenji, Matsumoto, Kunio, Yano, Seiji
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Impact Journals LLC 2014
विषय:
Research Paper
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4148110/
https://ncbi.nlm.nih.gov/pubmed/24952482
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन